Review the quality control efforts for prostate MR and explain the current and future applications of artificial intelligence on prostate imaging 3) Understand the potential roles and added value of PSMA PET and PET MR in the management of patients with prostate cancer 4) Identify the basics of ...
For a sixty-year old man with a PSA level of 1 ng/ml, the risk of prostate cancer on biopsy within 25 years was 12.6 and 25.0 times higher than the risk of metastases and death respectively; the comparable relative risks for a PSA of 4 ng / ml were 2.6 and 3.1. CONCLUSIONS ...
The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.
There are no warning signs of early prostate cancer. Learn more about the symptoms and signs of advanced prostate cancer and when you should call your doctor.
Prostate cancer causes vs. risk factors While there's no way to pinpoint the exact causes of prostate cancer, there are many things that increase your risk. Some people are more likely to get prostate cancer than others based on one or more gene variants they were born with. Lifestyle and...
aFailure to follow defined process 疏忽跟随被定义的过程 [translate] aandhesive andhesive [translate] aThere appears to be an excess of prostate cancer-associated deaths with IADT vs CADT 那里看来是摄护腺癌症伴生的死亡剩余与IADT对CADT [translate] ...
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683-2693.ArticlePubMedGoogle ScholarCrossref 66. Donovan JL, Hamdy FC, Lane JA, et al; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy ...
[3].Chi KN, et al. Final analysis results from TITAN: a phase 3 study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy. J Clin Oncol 39(6_suppl):11,2021). ...
Serum prostate-specific antigen (PSA) is currently the most used biomarker in clinical practice for prostate cancer (PCa) detection. However, this biomarker has several drawbacks. In this work, an untargeted gas chromatography-mass spectrometry (GC-MS)-based metabolomic profiling of PCa cells was ...
apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. 2022;25:139–48. Article CAS PubMed Google Scholar Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, et...